Minimal residual disease (MRD) testing continues to expand across precision oncology as advances in next-generation sequencing, circulating tumor DNA analysis, and tumor-informed assays broaden its potential applications in hematologic malignancies and solid tumors. MRD testing can provide clinicians with important information about treatment response, residual disease, and recurrence risk, supporting more informed clinical decision-making throughout the patient’s care journey. Read More >



